---
schema_version: "secwatch.filing_event.v1"
accession: "0001453687-26-000081"
form_type: "8-K"
ticker: "RNAC"
cik: "0001453687"
company_name: "Cartesian Therapeutics, Inc."
filed_at: "2026-04-30T23:59:59+00:00"
generated_at: "2026-05-15T00:40:03.812412+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cartesian Q1 net loss $39.2M ($1.46/sh) vs $17.7M; cash $120.4M; pipeline advances

## Summary
- Net loss widened to $39.2M from $17.7M YoY; higher R&D spend on Phase 3 AURORA trial.
- Cash, equivalents & restricted cash $120.4M as of March 31; raised $14.6M via ATM in Q1.
- Phase 3 AURORA trial enrollment continues; Phase 2 TRITON in myositis initiated; HELIOS pediatric trial progress.
- R&D expenses $19.5M (up 33% YoY) due to AURORA; G&A $7.1M (down 14% YoY).
- Cash runway expected into mid-2027, supporting completion of Phase 3 AURORA trial.

## SEC filing metadata
- accession: 0001453687-26-000081
- form_type: 8-K
- ticker: RNAC
- cik: 0001453687
- company_name: Cartesian Therapeutics, Inc.
- filed_at: 2026-04-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453687/000145368726000081/0001453687-26-000081-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453687/000145368726000081/rnac-20260430.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001453687-26-000081
- JSON: https://secwatch.observer/filing/0001453687-26-000081.json
- Plain text: https://secwatch.observer/filing/0001453687-26-000081.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.